IMVARIA, a Berkeley, California-based health tech company developing AI-driven digital biomarker solutions, announced it has secured strategic investments from new and existing investors to accelerate growth and expand its AI-powered diagnostic services.
The round was led by InHealth Ventures, an early-stage fund linked to screening and diagnostics provider InHealth Group, with participation from the Labcorp Venture Fund and existing partner Cedar Crest Holdings. Financial terms were not disclosed. IMVARIA said the capital will help extend its AI-driven diagnostic services for multiple forms of lung disease and improve access for clinicians, particularly pulmonologists.
Founded in 2019 by practicing physicians trained at Stanford School of Medicine who are also engineers formerly at Google, IMVARIA said it has earned two FDA authorizations for AI-powered tests and has built commercial traction around an approach designed to integrate AI into clinical workflows with minimal burden on providers.
IMVARIA’s flagship offering, Fibresolve, received FDA authorization in early 2024 for use in suspected interstitial lung disease, including idiopathic pulmonary fibrosis, according to the company. IMVARIA said the service is delivered through a centralized model that applies AI to help guide non-invasive diagnoses. The company also said Fibresolve holds FDA Breakthrough Device designation and has CPT billing codes adopted by the American Medical Association, which it said supports clinical ordering and reimbursement.
IMVARIA also said it recently received a Phase I Small Business Innovation Research grant from the National Institutes of Health to support development of a new test aimed at improving malignancy assessment in chest CT scans, building on its existing lung disease platform.
KEY QUOTES:
“We share a common mission and vision with our investors to leverage AI in diagnostic testing to make a significantly positive difference in patient care. The combination of the new strategic investments marks an important milestone in the emergence of IMVARIA as a leading AI-powered test services partner for the clinical community. We are currently focusing on non-invasive diagnoses for lung diseases, but we are also looking at opportunities to expand the applications of our AI platform and algorithms to support and help accelerate the evolution of healthcare.”
Joshua Reicher, MD, Co-Founder and CEO, IMVARIA
“At InHealth, we have confidence in IMVARIA’s health AI innovation and their medical credibility. Our valued partnership and our strategic investment in IMVARIA are part of a broader plan that we have to harness the power of AI to equip doctors and allied health professionals with more powerful tools and tests to transform how chronic disease is identified and treated.”
Richard Bradford, Chair, InHealth Group
“Our investment in IMVARIA reflects a shared vision for how AI can improve patient care through fast and efficient diagnostics. We’re proud to help shape the future of digital health by supporting innovative technologies that make healthcare more streamlined and effective.”
Megann Vaughn Watters, Vice President of New Ventures and Strategic Alliances, Labcorp
“We have made AI-driven testing for lung conditions extremely easy for pulmonologists to get new insights about patients that will help them have a richer set of data for making their own assessments. Because we are both doctors and technologists, we have been successfully able to deliver exactly what clinicians need, and the AMA’s adoption of CPT billing codes has made it easier for clinicians to order an IMVARIA AI test.”
Michael Muelly, MD, Co-Founder and CTO, IMVARIA
